Vicore Pharma Holding AB

NASDAQ:VCRE

Medical - Pharmaceuticals

Healthcare
$9.90 -1.66%

-$0.24 today

Market cap
$279.65M
Beta
0.15

Volume 0.00M

Average 0.26M

VCRE Net Margin

Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.

Vicore Pharma Holding ABNASDAQ: VCRE

Net Margin · Q2 FY2026 · quarter ended Jun 2026

Net margin widens to -6454.8%

Net margin was -6454.8% in Q2 FY2026, up 152.5 pp from a year earlier. On a trailing-twelve-month basis it was -20489.5%, down 11011.9 pp year over year.

What to watch

Whether net margin reaches the consensus estimate from 9 analysts of -8353.6% for the fiscal year ending Dec 2026, up from -12509.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-6454.8%+11587.7 pp QoQ
Last fiscal yearDec 2025
-12509.1%-12354.9 pp YoY
LTMJun 2026
-20489.5%-11011.9 pp YoY
Net Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+152.5 pp+1094.4 pp+941.9 pp
1 year-12354.9 pp+4155.6 pp+16510.5 pp
3 years—-139.4 pp—
5 years-2206.0 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Margin history

Percent of revenue · from the income statement

Latest · FY2025
-12509.1%
Year-over-year change
-12354.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Margin vs competitors

How VCRE compares with its peers on the latest reported figures

  • VCRE's LTM Jun 2026 net margin of -20489.5% is the lowest of the 2 companies compared; the peer median is 30.7%.
  • Its year-over-year change of -11011.9 pp is the lowest of 2, against a peer median of +762.9 pp.
VCRE Competitors Peer median
Net Margin for VCRE and competitors
Company Period LTM level YoY 3-year change
LQDALiquidia CorporationLTM Jun 202630.7% +762.9 pp+213.9 pp
VCREVicore Pharma Holding ABLTM Jun 2026-20489.5% -11011.9 pp—
AVLNAvalyn Pharma Inc. Common Stock—— ——
Peer median (excluding VCRE) 30.7%+762.9 pp+213.9 pp

Competitors are the stored peer set for VCRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

SEK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000109.35M3.82M
Cost of Revenue3.58M0000
Gross Profit(3.58M)00109.35M3.82M
Gross Margin———100.0%100.0%
Research & Development30.05M249.97M276.29M249.26M390.35M
Selling, General & Admin2.39M37.53M44.6M50.44M67.91M
Operating Expenses32.59M290.73M321.51M299.71M458.26M
Depreciation & Amortization371.33K3.61M3.42M2.24M0
EBITDA(32.07M)(285.19M)(307.9M)(166.64M)(477.41M)
EBITDA Margin———-152.4%-12507.6%
Operating Income(32.59M)(290.73M)(321.51M)(190.36M)(454.45M)
Operating Margin———-174.1%-11905.8%
Interest Income70.2K913K10.54M21.08M23.89M
Interest Expense08K2K8K60K
Other Income / Expenses(211.92K)1.92M10.18M21.47M(23.03M)
Income Before Tax(32.8M)(288.81M)(311.33M)(168.89M)(477.47M)
Pre-Tax Margin———-154.5%-12509.1%
Income Tax Expense(252.7K)(384K)(384K)(256K)0
Net Income(294.97M)(288.42M)(310.94M)(168.63M)(477.47M)
Net Margin———-154.2%-12509.1%
EPS (Basic)(0.47)(38.82)(31.80)(12.30)(19.90)
EPS (Diluted)(0.47)(38.82)(31.80)(12.30)(19.90)
Weighted Avg Shares69.68M7.42M9.66M13.68M23.99M
Weighted Avg Shares (Diluted)69.68M7.42M9.66M13.68M23.99M

Vicore Pharma Holding AB

NASDAQ:VCRE

Intrinsic Alpha fair value

Locked

Current Price

$9.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.